LARVOL Blog | ESMO 2021 Clinical Panel: GU

Author

LARVOL is pleased to present a moderated discussion with top oncologists following the ESMO Congress 2021. In the video below, Dr. Shilpa Gupta, Dr. Deepak Kilari and Dr. Bradley McGregor discuss the practice-changing impact of ESMO presentations in GU Cancers. 

On September 19th, 2021, LARVOL hosted an Oncology Panel to discuss the top Genitourinary Cancer clinical trial abstracts presented during the ESMO Congress 2021 , held on September 16-21, 2021. Dr. Shilpa Gupta from Cleveland Clinic Taussig Cancer Institute moderated the discussion between GU Cancer experts Dr. Deepak Kilari from Medical College of Wisconsin and Dr. Bradley McGregor from Dana-Farber Cancer Institute. 

The discussion covered ESMO GU Abstracts: 

‍661P: Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) 
‍660P: Phase III CLEAR Trial in Advanced Renal Cell Carcinoma (aRCC): Outcomes in Subgroups and Toxicity Update 
‍699P: Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the Phase II IMvigor210 study (Cohort 1)

‍ 

Watch this video for the full discussion: 

Download attached file

Get to Know the LARVOL Tigers: Marketing

Get to know the Tigers that make up each of LARVOL's dedicated teams.

Breast Cancer through LARVOL Eyes

This October, we are recognizing Breast Cancer Awareness Month with three very different takes on breast cancer from our organization and the Tigers who make us who we are.